Cantourage – the think tank for cannabinoid pharmaceuticals
Cantourage allows patients in Europe to benefit from innovative and competitive medical cannabis therapies. In order to achieve this, we work with leading international producers, manufacturers, logistics providers, distributors and pharmacies within and outside of Europe.
Enhancing the security of supplies, increasing the variety of offers, driving innovation – this is how Cantourage aims to make a lasting mark on the German market for medical cannabis for the benefit of patients.
Cantourage is in possession of all relevant licenses required under pharmaceutical and narcotics law.
Cantourage is a new player on the market – however, part of its founding team belongs to the pioneers of the medical cannabis market in Germany: Dr. Florian Holzapfel and Patrick Hoffmann, as founders, developed Pedanios into the European market leader in the field of cannabis flowers. Now Cantourage continues to shape the medical cannabis market in both Germany and Europe.
“We are shaping the medical cannabis market with new ideas and concepts. Our aim is to provide patients with serious assistance.”
The Cantourage Team
The brains behind Cantourage are experts in the medical cannabis business, who in various functions have shaped the still young market for cannabinoid-containing pharmaceuticals in Germany and Europe. In their careers to date, several team members founded, among other things, Europe’s first wholesaler specializing in cannabis-based medicines. In addition, the team was responsible for the export of cannabis flowers and cannabis extracts to seven European countries as well as the award of cultivation licenses in Germany, among other places.
Cantourage sells products made from the raw material of the cannabis plant. All products are manufactured under GMP (Good Manufacturing Practice) conditions and are subject to constant quality controls.
The provisions of the Narcotics Act prohibit the advertising of drugs and narcotics. Since cannabis is classified under narcotics legislation in accordance with Annex III of the German Narcotic Drugs Act [BtMG], no references, product descriptions or illustrations of Cantourage products may be published or advertised. Violations of this prohibition constitute a criminal offence. If you would like to learn more about cannabis flowers or the active ingredient and its therapeutic uses, then please contact your attending physician or pharmacist.
We are happy to provide pharmacists with comprehensive advice about our products by telephone. A restricted area with information about our products will also be activated soon.
We offer physicians the opportunity to discuss questions about our products, their prescription and performance with our team of experts. We would also be pleased to visit you personally on site.
We would be pleased if you are interested in Cantourage and would like to work with us. We would be happy to discuss investment opportunities with you in person.
Here you can download our press release on the launch of our product Dronabinol: Press release Cantourage, from April 15, 2020
We are happy to immediately provide journalists with the corresponding press kit on request.
We are also available for all other press inquiries.